ID PFKAM_MOUSE Reviewed; 780 AA. AC P47857; C8CMN5; C8CMN6; C8CMN7; O35513; Q543L1; Q9JK94; DT 01-FEB-1996, integrated into UniProtKB/Swiss-Prot. DT 23-JAN-2007, sequence version 3. DT 27-MAR-2024, entry version 206. DE RecName: Full=ATP-dependent 6-phosphofructokinase, muscle type {ECO:0000255|HAMAP-Rule:MF_03184}; DE Short=ATP-PFK {ECO:0000255|HAMAP-Rule:MF_03184}; DE Short=PFK-M; DE EC=2.7.1.11 {ECO:0000255|HAMAP-Rule:MF_03184}; DE AltName: Full=6-phosphofructokinase type A; DE AltName: Full=Phosphofructo-1-kinase isozyme A; DE Short=PFK-A; DE AltName: Full=Phosphohexokinase {ECO:0000255|HAMAP-Rule:MF_03184}; GN Name=Pfkm; Synonyms=Pfk-m, Pfka; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Mus; Mus. OX NCBI_TaxID=10090; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC STRAIN=SWR/J; TISSUE=Brain; RX PubMed=11137296; DOI=10.1016/s0378-1119(00)00463-7; RA Gunasekera D., Kemp R.G.; RT "Genomic organization, 5'flanking region and tissue-specific expression of RT mouse phosphofructokinase C gene."; RL Gene 260:103-112(2000). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND PARTIAL NUCLEOTIDE RP SEQUENCE [MRNA] (ISOFORM 3). RC STRAIN=C57BL/6J; RC TISSUE=Kidney, Spinal cord, and Thymus {ECO:0000312|EMBL:AK138788}; RX PubMed=16141072; DOI=10.1126/science.1112014; RA Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N., RA Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K., RA Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J., RA Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R., RA Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T., RA Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A., RA Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., RA Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M., RA Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S., RA Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E., RA Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D., RA Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M., RA Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H., RA Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V., RA Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S., RA Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H., RA Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N., RA Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F., RA Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., RA Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., RA Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C., RA Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y., RA Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S., RA Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K., RA Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R., RA van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H., RA Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M., RA Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C., RA Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S., RA Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K., RA Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M., RA Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C., RA Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A., RA Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.; RT "The transcriptional landscape of the mammalian genome."; RL Science 309:1559-1563(2005). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1-213 (ISOFORM 1), AND NUCLEOTIDE SEQUENCE RP [GENOMIC DNA] OF 259-345. RC STRAIN=ICR; RX PubMed=7980403; DOI=10.1042/bj3030449; RA Nakajima H., Noguchi T., Hamaguchi T., Tomita K., Hanafusa T., Kono N., RA Tanaka T., Kuwajima M., Matsuzawa Y.; RT "Expression of mouse phosphofructokinase-M gene alternative transcripts: RT evidence for the conserved two-promoter system."; RL Biochem. J. 303:449-453(1994). RN [4] RP PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, CATALYTIC RP ACTIVITY, INTERACTION WITH GSTM5 AND HK1, SUBCELLULAR LOCATION, ALTERNATIVE RP SPLICING, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE. RC STRAIN=C57BL/6J {ECO:0000312|EMBL:ACU65459.1}; RX PubMed=19889946; DOI=10.1095/biolreprod.109.080580; RA Nakamura N., Mori C., Eddy E.M.; RT "Molecular complex of three testis-specific isozymes associated with the RT mouse sperm fibrous sheath: hexokinase 1, phosphofructokinase M, and RT glutathione S-transferase mu class 5."; RL Biol. Reprod. 82:504-515(2010). RN [5] RP PROTEIN SEQUENCE OF 367-374, AND IDENTIFICATION BY MASS SPECTROMETRY. RC STRAIN=C57BL/6J; TISSUE=Brain; RA Lubec G., Kang S.U.; RL Submitted (APR-2007) to UniProtKB. RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Liver, Lung, RC Pancreas, Spleen, and Testis; RX PubMed=21183079; DOI=10.1016/j.cell.2010.12.001; RA Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R., RA Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.; RT "A tissue-specific atlas of mouse protein phosphorylation and expression."; RL Cell 143:1174-1189(2010). CC -!- FUNCTION: Catalyzes the phosphorylation of D-fructose 6-phosphate to CC fructose 1,6-bisphosphate by ATP, the first committing step of CC glycolysis. {ECO:0000255|HAMAP-Rule:MF_03184, CC ECO:0000269|PubMed:19889946}. CC -!- CATALYTIC ACTIVITY: CC Reaction=ATP + beta-D-fructose 6-phosphate = ADP + beta-D-fructose 1,6- CC bisphosphate + H(+); Xref=Rhea:RHEA:16109, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:30616, ChEBI:CHEBI:32966, ChEBI:CHEBI:57634, CC ChEBI:CHEBI:456216; EC=2.7.1.11; Evidence={ECO:0000255|HAMAP- CC Rule:MF_03184, ECO:0000269|PubMed:19889946}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC -!- ACTIVITY REGULATION: Allosterically activated by ADP, AMP, or fructose CC 2,6-bisphosphate, and allosterically inhibited by ATP or citrate. CC {ECO:0000255|HAMAP-Rule:MF_03184}. CC -!- PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3- CC phosphate and glycerone phosphate from D-glucose: step 3/4. CC {ECO:0000255|HAMAP-Rule:MF_03184}. CC -!- SUBUNIT: Homo- and heterotetramers (By similarity). Phosphofructokinase CC (PFK) enzyme functions as a tetramer composed of different combinations CC of 3 types of subunits, called PFKM (M), PFKL (L) and PFKP (P). The CC composition of the PFK tetramer differs according to the tissue type it CC is present in. The kinetic and regulatory properties of the tetrameric CC enzyme are dependent on the subunit composition, hence can vary across CC tissues (Probable). Isoform 2 and isoform 3 interact (via N-terminal CC testis-specific region) with GSTM5. Isoform 2 and isoform 3 interact CC (via C-terminus) with HK1 (via N-terminal spermatogenic cell-specific CC region). {ECO:0000255|HAMAP-Rule:MF_03184, ECO:0000269|PubMed:19889946, CC ECO:0000305}. CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03184}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell projection, cilium, flagellum CC {ECO:0000269|PubMed:19889946}. Note=Principal piece region of the sperm CC flagellum. {ECO:0000269|PubMed:19889946}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Cell projection, cilium, flagellum CC {ECO:0000269|PubMed:19889946}. Note=Principal piece region of the sperm CC flagellum. {ECO:0000269|PubMed:19889946}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; CC IsoId=P47857-1; Sequence=Displayed; CC Name=2; Synonyms=Pfkms_V4 {ECO:0000303|PubMed:19889946}; CC IsoId=P47857-2; Sequence=VSP_057079; CC Name=3; Synonyms=Pfkms_V3 {ECO:0000303|PubMed:19889946}; CC IsoId=P47857-3; Sequence=VSP_057080; CC -!- TISSUE SPECIFICITY: Isoform 1 is expressed in skeletal muscle (at CC protein level). Isoform 2 and isoform 3 are testis-specific and are CC detected in quiescent sperm (at protein level). They are first detected CC in the cytoplasm of round spermatids and subsequently in the flagellum CC of elongated spermatids extending into the seminiferous tubule lumen CC (at protein level). Isoform 2 is expressed at higher level than isoform CC 3 in testis. {ECO:0000269|PubMed:19889946}. CC -!- DEVELOPMENTAL STAGE: Isoform 2 and isoform 3 are first seen on CC postnatal day 16 corresponding to the age when midpachytene CC spermatocytes are present in the synchronous first wave of CC spermatogenesis. Isoform 2 and isoform 3 levels increase substantially CC between days 14 and 18 and continue to increase to age 30 days of CC neonatal testis development. {ECO:0000269|PubMed:19889946}. CC -!- PTM: GlcNAcylation decreases enzyme activity. {ECO:0000250}. CC -!- SIMILARITY: Belongs to the phosphofructokinase type A (PFKA) family. CC ATP-dependent PFK group I subfamily. Eukaryotic two domain clade 'E' CC sub-subfamily. {ECO:0000255|HAMAP-Rule:MF_03184}. CC -!- SEQUENCE CAUTION: CC Sequence=AK138788; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305|PubMed:19889946}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF249894; AAF63762.1; -; mRNA. DR EMBL; AK002711; BAB22303.1; -; mRNA. DR EMBL; AK049773; BAC33913.1; -; mRNA. DR EMBL; AK138788; -; NOT_ANNOTATED_CDS; mRNA. DR EMBL; D21864; BAA21892.1; -; Genomic_DNA. DR EMBL; D21865; BAA21012.1; -; mRNA. DR EMBL; GQ428204; ACU65458.1; -; mRNA. DR EMBL; GQ428205; ACU65459.1; -; mRNA. DR EMBL; GQ428206; ACU65460.1; -; mRNA. DR CCDS; CCDS27786.1; -. [P47857-1] DR PIR; S53317; S53317. DR RefSeq; NP_001156959.1; NM_001163487.1. [P47857-1] DR RefSeq; NP_001156960.1; NM_001163488.1. [P47857-1] DR RefSeq; NP_067489.3; NM_021514.4. [P47857-1] DR RefSeq; XP_006520664.1; XM_006520601.3. [P47857-2] DR RefSeq; XP_006520665.1; XM_006520602.2. DR AlphaFoldDB; P47857; -. DR SMR; P47857; -. DR BioGRID; 202125; 33. DR ComplexPortal; CPX-2049; 6-phosphofructokinase, M4 homotetramer. DR ComplexPortal; CPX-2055; 6-phosphofructokinase, ML3 heterotetramer. DR ComplexPortal; CPX-2056; 6-phosphofructokinase, M2L2 heterotetramer. DR ComplexPortal; CPX-2057; 6-phosphofructokinase, M3L heterotetramer. DR IntAct; P47857; 7. DR MINT; P47857; -. DR STRING; 10090.ENSMUSP00000059801; -. DR GlyCosmos; P47857; 1 site, No reported glycans. DR GlyGen; P47857; 2 sites, 1 O-linked glycan (1 site). DR iPTMnet; P47857; -. DR MetOSite; P47857; -. DR PhosphoSitePlus; P47857; -. DR SwissPalm; P47857; -. DR EPD; P47857; -. DR jPOST; P47857; -. DR MaxQB; P47857; -. DR PaxDb; 10090-ENSMUSP00000059801; -. DR PeptideAtlas; P47857; -. DR ProteomicsDB; 288100; -. [P47857-1] DR ProteomicsDB; 288101; -. [P47857-2] DR ProteomicsDB; 288102; -. [P47857-3] DR Pumba; P47857; -. DR Antibodypedia; 1061; 520 antibodies from 37 providers. DR DNASU; 18642; -. DR Ensembl; ENSMUST00000051226.8; ENSMUSP00000059801.7; ENSMUSG00000033065.15. [P47857-1] DR Ensembl; ENSMUST00000163507.8; ENSMUSP00000132803.2; ENSMUSG00000033065.15. [P47857-1] DR Ensembl; ENSMUST00000230445.2; ENSMUSP00000155809.2; ENSMUSG00000033065.15. [P47857-1] DR GeneID; 18642; -. DR KEGG; mmu:18642; -. DR UCSC; uc007xlv.2; mouse. [P47857-1] DR AGR; MGI:97548; -. DR CTD; 5213; -. DR MGI; MGI:97548; Pfkm. DR VEuPathDB; HostDB:ENSMUSG00000033065; -. DR eggNOG; KOG2440; Eukaryota. DR GeneTree; ENSGT00940000155440; -. DR HOGENOM; CLU_011053_0_0_1; -. DR InParanoid; P47857; -. DR OMA; WHNLGGS; -. DR OrthoDB; 374214at2759; -. DR PhylomeDB; P47857; -. DR TreeFam; TF300411; -. DR Reactome; R-MMU-70171; Glycolysis. DR SABIO-RK; P47857; -. DR UniPathway; UPA00109; UER00182. DR BioGRID-ORCS; 18642; 3 hits in 77 CRISPR screens. DR ChiTaRS; Pfkm; mouse. DR PRO; PR:P47857; -. DR Proteomes; UP000000589; Chromosome 15. DR RNAct; P47857; Protein. DR Bgee; ENSMUSG00000033065; Expressed in triceps brachii and 263 other cell types or tissues. DR ExpressionAtlas; P47857; baseline and differential. DR GO; GO:0005945; C:6-phosphofructokinase complex; ISO:MGI. DR GO; GO:0016324; C:apical plasma membrane; ISO:MGI. DR GO; GO:0005829; C:cytosol; IDA:MGI. DR GO; GO:0016020; C:membrane; IBA:GO_Central. DR GO; GO:0005634; C:nucleus; ISO:MGI. DR GO; GO:0097228; C:sperm principal piece; IDA:MGI. DR GO; GO:0003872; F:6-phosphofructokinase activity; IDA:MGI. DR GO; GO:0016208; F:AMP binding; ISO:MGI. DR GO; GO:0005524; F:ATP binding; ISO:MGI. DR GO; GO:0030246; F:carbohydrate binding; ISO:MGI. DR GO; GO:0070061; F:fructose binding; ISO:MGI. DR GO; GO:0070095; F:fructose-6-phosphate binding; ISO:MGI. DR GO; GO:0042802; F:identical protein binding; IPI:MGI. DR GO; GO:0019900; F:kinase binding; ISO:MGI. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0048029; F:monosaccharide binding; IBA:GO_Central. DR GO; GO:0008443; F:phosphofructokinase activity; IDA:MGI. DR GO; GO:0061621; P:canonical glycolysis; IDA:MGI. DR GO; GO:0030388; P:fructose 1,6-bisphosphate metabolic process; ISO:MGI. DR GO; GO:0006002; P:fructose 6-phosphate metabolic process; ISO:MGI. DR GO; GO:0042593; P:glucose homeostasis; IMP:MGI. DR GO; GO:0005980; P:glycogen catabolic process; IMP:MGI. DR GO; GO:0093001; P:glycolysis from storage polysaccharide through glucose-1-phosphate; IMP:MGI. DR GO; GO:0006096; P:glycolytic process; ISO:MGI. DR GO; GO:0061615; P:glycolytic process through fructose-6-phosphate; IDA:MGI. DR GO; GO:0046716; P:muscle cell cellular homeostasis; ISO:MGI. DR GO; GO:0032024; P:positive regulation of insulin secretion; IMP:MGI. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISO:MGI. DR CDD; cd00764; Eukaryotic_PFK; 1. DR Gene3D; 3.40.50.450; -; 2. DR Gene3D; 3.40.50.460; Phosphofructokinase domain; 2. DR HAMAP; MF_03184; Phosphofructokinase_I_E; 1. DR InterPro; IPR009161; 6-Pfructokinase_euk. DR InterPro; IPR022953; ATP_PFK. DR InterPro; IPR041914; PFK_vert-type. DR InterPro; IPR015912; Phosphofructokinase_CS. DR InterPro; IPR000023; Phosphofructokinase_dom. DR InterPro; IPR035966; PKF_sf. DR NCBIfam; TIGR02478; 6PF1K_euk; 1. DR PANTHER; PTHR13697:SF59; ATP-DEPENDENT 6-PHOSPHOFRUCTOKINASE, MUSCLE TYPE; 1. DR PANTHER; PTHR13697; PHOSPHOFRUCTOKINASE; 1. DR Pfam; PF00365; PFK; 2. DR PIRSF; PIRSF000533; ATP_PFK_euk; 1. DR PRINTS; PR00476; PHFRCTKINASE. DR SUPFAM; SSF53784; Phosphofructokinase; 2. DR PROSITE; PS00433; PHOSPHOFRUCTOKINASE; 2. DR Genevisible; P47857; MM. PE 1: Evidence at protein level; KW Acetylation; Allosteric enzyme; Alternative splicing; ATP-binding; KW Cell projection; Cilium; Cytoplasm; Direct protein sequencing; Flagellum; KW Glycolysis; Glycoprotein; Hydroxylation; Kinase; Magnesium; Metal-binding; KW Nucleotide-binding; Phosphoprotein; Reference proteome; Transferase. FT INIT_MET 1 FT /note="Removed" FT /evidence="ECO:0000250|UniProtKB:P00511" FT CHAIN 2..780 FT /note="ATP-dependent 6-phosphofructokinase, muscle type" FT /id="PRO_0000112018" FT REGION 2..390 FT /note="N-terminal catalytic PFK domain 1" FT REGION 391..401 FT /note="Interdomain linker" FT REGION 402..780 FT /note="C-terminal regulatory PFK domain 2" FT ACT_SITE 166 FT /note="Proton acceptor" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 25 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 88..89 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 118..121 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 119 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_note="catalytic" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 164..166 FT /ligand="substrate" FT /ligand_note="ligand shared between dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 201 FT /ligand="substrate" FT /ligand_note="ligand shared between dimeric partners" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 208..210 FT /ligand="substrate" FT /ligand_note="ligand shared between dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 264 FT /ligand="substrate" FT /ligand_note="ligand shared between dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 292 FT /ligand="substrate" FT /ligand_note="ligand shared between dimeric partners" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 298..301 FT /ligand="substrate" FT /ligand_note="ligand shared between dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 471 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 528..532 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 566 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 573..575 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 629 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 655 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 661..664 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT BINDING 735 FT /ligand="beta-D-fructose 2,6-bisphosphate" FT /ligand_id="ChEBI:CHEBI:58579" FT /ligand_note="allosteric activator; ligand shared between FT dimeric partners" FT /note="in other chain" FT /evidence="ECO:0000255|HAMAP-Rule:MF_03184" FT MOD_RES 2 FT /note="N-acetylthreonine" FT /evidence="ECO:0000250|UniProtKB:P00511" FT MOD_RES 133 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P47858" FT MOD_RES 377 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21183079" FT MOD_RES 557 FT /note="N6-(2-hydroxyisobutyryl)lysine" FT /evidence="ECO:0000250|UniProtKB:P08237" FT MOD_RES 667 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P08237" FT MOD_RES 775 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P00511" FT CARBOHYD 530 FT /note="O-linked (GlcNAc) serine" FT /evidence="ECO:0000250" FT VAR_SEQ 1 FT /note="M -> MRREEFQLRFFMCVIESRQVVRTTQSTAGEASTSNMTIPESKADDQW FT RLDGMDDDPSTVGPVSIPDTEWIM (in isoform 2)" FT /evidence="ECO:0000269|PubMed:19889946" FT /id="VSP_057079" FT VAR_SEQ 1 FT /note="M -> MEEKLTCSFKLLTELLNLITPLAQALFGKRLQNSILDPGDCLSEFTL FT EERKASGICQPHLFSKHKEINLFLQGILTCYEVAMRREEFQLRFFMCVIESRQVVRTTQ FT STAGEASTSNMTIPESKADDQWRLDGMDDDPSTVGPVSIPDTEWIM (in isoform FT 3)" FT /evidence="ECO:0000303|PubMed:19889946" FT /id="VSP_057080" SQ SEQUENCE 780 AA; 85269 MW; 7917C7AC108B25C7 CRC64; MTHEEHHAAK TLGIGKAIAV LTSGGDAQGM NAAVRAVVRV GIFTGARVFF VHEGYQGLVD GGEHIREATW ESVSMMLQLG GTVIGSARCK DFREREGRLR AAHNLVKRGI TNLCVIGGDG SLTGADTFRS EWSDLLNDLQ KDGKITAEEA TKSSYLNIVG LVGSIDNDFC GTDMTIGTDS ALHRIVEIVD AITTTAQSHQ RTFVLEVMGR HCGYLALVTS LSCGADWVFI PECPPDDDWE EHLCRRLSET RTRGSRLNII IVAEGAIDKN GKPITSEDIK NLVVKRLGYD TRVTVLGHVQ RGGTPSAFDR ILGSRMGVEA VMALLEGTPD TPACVVSLSG NQAVRLPLME CVQVTKDVTK AMDEKRFDEA IKLRGRSFMN NWEVYKLLAH VRPPVSKGGL HTVAVMNVGA PAAGMNAAVR STVRIGLIQG NRVLVVHDGF EGLAKGQIEE AGWSYVGGWT GQGGSKLGTK RTLPKKNLEQ ISANITKFNI QGLVIIGGFE AYTGGLELME GRKQFDELCI PFVVIPATVS NNVPGSDFSI GADTALNTIC TTCDRIKQSA AGTKRRVFII ETMGGYCGYL ATMAGLAAGA DAAYIFEEPF TIRDLQVNVE HLVQKMKTTV KRGLVLRNEK CNENYTTDFI FNLYSEEGKG IFDSRKNVLG HMQQGGSPTP FDRNFATKMG AKAMNWMSGK IKESYRNGRI FANTPDSGCV LGMRKRALVF QPVTELKDQT DFEHRIPKEQ WWLKLRPILK ILAKYEIDLD TSDHAHLEHI SRKRSGEAAV //